EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

Olga Lomovskaya iD, Mariana Castanheira, Jill Lindley, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, Dongxu Sun, Maxim Totrov, Jeffery Loutit, Michael Dudley

Antimicrobial Agents and Chemotherapy · 15.11.2023 · 67 (11)

DOI: 10.1128/aac.00440-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 15.11.2023. Verfasst von Olga Lomovskaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Qpex Biopharma , San Diego, California, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, HHS | Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, several β-lactam (BL)/β-lactamase inhibitor (BLI) combinations have entered clinical testing or have been marketed for use, but limited direct comparative studies of their in vitro activity exist. Xeruborbactam (XER, also known as QPX7728), which is undergoing clinical development, is a cyclic boronate BLI with potent inhibitory activity against serine (serine β-lactamase) and metallo-β-lactamases (MBLs). The objectives of this study were (i) to compare the potency and spectrum of β-lactamase inhibition by various BLIs in biochemical assays using purified β-lactamases and in microbiological assays using the panel of laboratory strains expressing diverse serine and metallo-β-lactamases and (ii) to compare the in vitro potency of XER in combination with multiple β-lactam antibiotics to that of other BL/BLI combinations in head-to-head testing against recent isolates of carbapenem-resistant Enterobacterales (CRE). Minimal inhibitory concentrations (MICs) of XER combinations were tested with XER at fixed 4 or 8 µg/mL, and MIC testing was conducted in a blinded fashion using Clinical and Laboratory Standards Institute reference methods. Xeruborbactam and taniborbactam (TAN) were the only BLIs that inhibited clinically important MBLs. The spectrum of activity of xeruborbactam included several MBLs identified in Enterobacterales, e.g., and various IMP enzymes and NDM-9 that were not inhibited by taniborbactam. Xeruborbactam potency against the majority of purified β-lactamases was the highest in comparison with other BLIs. Meropenem-xeruborbactam (MEM-XER, fixed 8 µg/mL) was the most potent combination against MBL-negative CRE with MIC 90 values of 0.125 µg/mL. MEM-XER and cefepime-taniborbactam (FEP-TAN) were the only BL/BLIs with activity against MBL-producing CREs; with MEM-XER (MIC 90 of 1 µg/mL) being at least 16-fold more potent than FEP-TAN (MIC 90 of 16 µg/mL). MEM-XER MIC values were ≤8 µg/mL for >90% of CRE, including both MBL-negative and MBL-positive isolates, with FEP-TAN MIC of >8 µg/mL. Xeruborbactam also significantly enhanced potency of other β-lactam antibiotics, including cefepime, ceftolozane, ceftriaxone, aztreonam, piperacillin, and ertapenem, against clinical isolates of Enterobacterales that carried various class A, class C, and class D extended-spectrum β-lactamases and carbapenem-resistant Enterobacterales , including metallo-β-lactamase-producing isolates. These results strongly support further clinical development of xeruborbactam combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsCarbapenemsbeta Lactam AntibioticsCefepimeLactamsbeta-LactamasesSerineMicrobial Sensitivity TestsAzabicyclo CompoundsBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

CREavibactamcarbapenemasesmetallo-β-lactamasesrelebactamtaniborbactamvaborbactamxeruborbactam

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial AgentsCarbapenemsbeta Lactam AntibioticsCefepimeLactamsbeta-LactamasesSerineAzabicyclo Compoundstaniborbactam

Autor:innen und Institutionen

  • Qpex Biopharma , San Diego, California, USA.
  • JMI Laboratories , North Liberty, lowa, USA.
  • Molsoft, LLC , San Diego, California, USA.

ORCID-Profile: Olga Lomovskaya

Förderung

  • NIH HHS
  • HHS | Biomedical Advanced Research and Development Authority

Zitieren

APA

Lomovskaya, O., Castanheira, M., Lindley, J., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Sun, D., Totrov, M., Loutit, J., & Dudley, M. (2023). In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/aac.00440-23

Vancouver

Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, et al. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy. 2023;67(11). doi:10.1128/aac.00440-23

BibTeX
@article{Lomovskaya2023,
  author = {Lomovskaya, Olga and Castanheira, Mariana and Lindley, Jill and Rubio-Aparicio, Debora and Nelson, Kirk and Tsivkovski, Ruslan and Sun, Dongxu and Totrov, Maxim and Loutit, Jeffery and Dudley, Michael},
  title = {In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {11},
  doi = {10.1128/aac.00440-23}
}
Kostenlos starten →